Arteris, Inc. (NASDAQ:AIP – Get Free Report) Director Saiyed Atiq Raza sold 41,439 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $10.37, for a total value of $429,722.43. Following the sale, the director now owns 690,121 shares of the company’s stock, valued at approximately $7,156,554.77. This represents a 5.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Saiyed Atiq Raza also recently made the following trade(s):
- On Wednesday, December 18th, Saiyed Atiq Raza sold 12,166 shares of Arteris stock. The stock was sold at an average price of $10.07, for a total value of $122,511.62.
- On Wednesday, December 11th, Saiyed Atiq Raza sold 2,400 shares of Arteris stock. The shares were sold at an average price of $10.01, for a total transaction of $24,024.00.
Arteris Stock Down 1.5 %
AIP stock opened at $10.19 on Wednesday. Arteris, Inc. has a 52 week low of $4.83 and a 52 week high of $10.69. The business has a 50-day simple moving average of $8.62 and a 200 day simple moving average of $7.98. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The company has a market cap of $409.40 million, a PE ratio of -10.61 and a beta of 1.25.
Hedge Funds Weigh In On Arteris
Analyst Upgrades and Downgrades
Separately, Rosenblatt Securities reiterated a “buy” rating and issued a $15.00 price target on shares of Arteris in a research report on Wednesday, November 6th.
Get Our Latest Research Report on Arteris
Arteris Company Profile
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.
Further Reading
- Five stocks we like better than Arteris
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Stocks Helping to Bring AI to Healthcare
- What is MarketRank™? How to Use it
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 3 Monster Growth Stocks to Buy Now
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.